Dr. Jonathan Hill Joins SpectraWAVE as Chief Medical Officer

SpectraWAVE Inc. has appointed Jonathan Hill, M.D., as chief medical officer. A globally renowned interventional cardiologist from Royal Brompton Hospital in London, Dr. Hill has extensive expertise in coronary artery disease, complex PCI, intravascular imaging, physiology, cardiovascular innovation, and clinical study design and implementation.

“Jonathan is a highly respected clinician and innovator whose leadership will be critical as SpectraWAVE accelerates commercial adoption and advances its clinical evidence strategy both in the U.S. and worldwide for our expanding product portfolio,” SpectraWAVE CEO Eman Namati, Ph.D., said. “His experience integrating intravascular imaging and physiology into daily clinical practice, and being at the front lines of medicine with multiple major worldwide clinical studies will strengthen our partnerships with physicians, research groups, and support our commitment to improving outcomes for CAD patients.”

The announcement occurs as SpectraWAVE surpasses thousands of commercial HyperVue Imaging System cases in U.S. catheter labs and achieves multiple clinical study milestones. The company recently completed enrollment of a 175-patient U.S. clinical workflow study of HyperVue, its state-of-the-art DeepOCT+NIRS intravascular imaging system, with results presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting October. In addition, SpectraWAVE has initiated a multi-site U.S. study evaluating its upcoming single-angiogram wire-free FFR technology, currently under review by the U.S. Food and Drug Administration.

“I am honored to join SpectraWAVE at such a pivotal time,” Dr. Hill stated. “The company’s approach to combining intravascular imaging and physiology in a comprehensive and easy-to-use form factor is going to transform decision-making in the catheter lab. I look forward to collaborating with the team and the global clinical community as we expand the impact of HyperVue and introduce new technologies and clinical indications beyond intravascular imaging.”

Based in Bedford, Mass., SpectraWAVE is a privately held medical device company founded in 2017 to provide optical and computational insights to improve the treatment and outcomes for coronary artery disease (CAD) patients. CAD is plaque buildup in the wall of the arteries supplying blood to the heart; the disease affects 20.5 million adults aged 20 and older. In CAD patients that undergo percutaneous stent placement, an estimated one in five patients experience adverse events within two years.

SpectraWAVE’s flagship HyperVue Imaging System combines next-generation DeepOCT images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab, and serves as a central hub for future enhancements that empower interventionalists in their treatment decision-making and optimization. The HyperVue Imaging System is intended to image coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended to identify patients and plaques at increased risk of major adverse cardiac events.